Excess ischemic tachyarrhythmias trigger protection against myocardial infarction in hypertensive rats.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
17 09 2021
Historique:
received: 22 06 2021
revised: 17 08 2021
accepted: 03 09 2021
pubmed: 7 9 2021
medline: 15 12 2021
entrez: 6 9 2021
Statut: ppublish

Résumé

Increased level of C-reactive protein (CRP) is a risk factor for cardiovascular diseases, including myocardial infarction and hypertension. Here, we analyzed the effects of CRP overexpression on cardiac susceptibility to ischemia/reperfusion (I/R) injury in adult spontaneously hypertensive rats (SHR) expressing human CRP transgene (SHR-CRP). Using an in vivo model of coronary artery occlusion, we found that transgenic expression of CRP predisposed SHR-CRP to repeated and prolonged ventricular tachyarrhythmias. Excessive ischemic arrhythmias in SHR-CRP led to a significant reduction in infarct size (IS) compared with SHR. The proarrhythmic phenotype in SHR-CRP was associated with altered heart and plasma eicosanoids, myocardial composition of fatty acids (FAs) in phospholipids, and autonomic nervous system imbalance before ischemia. To explain unexpected IS-limiting effect in SHR-CRP, we performed metabolomic analysis of plasma before and after ischemia. We also determined cardiac ischemic tolerance in hearts subjected to remote ischemic perconditioning (RIPer) and in hearts ex vivo. Acute ischemia in SHR-CRP markedly increased plasma levels of multiple potent cardioprotective molecules that could reduce IS at reperfusion. RIPer provided IS-limiting effect in SHR that was comparable with myocardial infarction observed in naïve SHR-CRP. In hearts ex vivo, IS did not differ between the strains, suggesting that extra-cardiac factors play a crucial role in protection. Our study shows that transgenic expression of human CRP predisposes SHR-CRP to excess ischemic ventricular tachyarrhythmias associated with a drop of pump function that triggers myocardial salvage against lethal I/R injury likely mediated by protective substances released to blood from hypoxic organs and tissue at reperfusion.

Identifiants

pubmed: 34486670
pii: 229720
doi: 10.1042/CS20210648
doi:

Substances chimiques

C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2143-2163

Informations de copyright

© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Jan Neckář (J)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.
Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Petra Alánová (P)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Veronika Olejníčková (V)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.
Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic.

František Papoušek (F)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Lucie Hejnová (L)

Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.

Jan Šilhavý (J)

Laboratory of Genetics of Model Diseases, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Michal Behuliak (M)

Laboratory of Experimental Hypertension, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Michal Bencze (M)

Laboratory of Experimental Hypertension, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Jaroslav Hrdlička (J)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Marek Vecka (M)

4th Department of Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Dagmar Jarkovská (D)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.

Jitka Švíglerová (J)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.

Eliška Mistrová (E)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.

Milan Štengl (M)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.

Jiří Novotný (J)

Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.

Bohuslav Ošťádal (B)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Michal Pravenec (M)

Laboratory of Genetics of Model Diseases, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

František Kolář (F)

Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH